Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis

Colorectal cancer; Bevacizumab; Decision making

Detalles Bibliográficos
Autores: Calle, Candela, Elez, Elena, Moreno-Martinez, Maria-Estela, Pericay, Carles, Graefenhain, Ruth, MANZANO, JOSE LUIS
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:dnet:scientia____::238c5b2bc00794a4af3600b0d4f5eff6
Acceso en línea:http://hdl.handle.net/11351/14293
Access Level:acceso abierto
Palabra clave:Metàstasi
Recte - Càncer - Tractament
Còlon - Càncer - Tractament
Quimioteràpia combinada
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
id ES_ccf7885ea48b32b2a59cca4e746e9ede
oai_identifier_str oai:dnet:scientia____::238c5b2bc00794a4af3600b0d4f5eff6
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
title Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
spellingShingle Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
Calle, Candela
Metàstasi
Recte - Càncer - Tractament
Còlon - Càncer - Tractament
Quimioteràpia combinada
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
title_short Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
title_full Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
title_fullStr Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
title_full_unstemmed Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
title_sort Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysis
dc.creator.none.fl_str_mv Calle, Candela
Elez, Elena
Moreno-Martinez, Maria-Estela
Pericay, Carles
Graefenhain, Ruth
MANZANO, JOSE LUIS
author Calle, Candela
author_facet Calle, Candela
Elez, Elena
Moreno-Martinez, Maria-Estela
Pericay, Carles
Graefenhain, Ruth
MANZANO, JOSE LUIS
author_role author
author2 Elez, Elena
Moreno-Martinez, Maria-Estela
Pericay, Carles
Graefenhain, Ruth
MANZANO, JOSE LUIS
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Calle C] Fundació Sant Francesc d’Assís, Barcelona, Spain. [Elez E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Manzano JL] Catalan Institute of Oncology, Hospital Germans Trials i Pujol, Barcelona, Spain. [Moreno-Martinez ME] Servei de Farmàcia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Pericay C] Hospital Universitari Mútua de Terrassa, Barcelona, Spain. [Graefenhain R] Servier España, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Metàstasi
Recte - Càncer - Tractament
Còlon - Càncer - Tractament
Quimioteràpia combinada
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
topic Metàstasi
Recte - Càncer - Tractament
Còlon - Càncer - Tractament
Quimioteràpia combinada
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
description Colorectal cancer; Bevacizumab; Decision making
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11351/14293
url http://hdl.handle.net/11351/14293
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Journal of Pharmaceutical Policy and Practice;18(1)
https://doi.org/10.1080/20523211.2025.2567970
dc.rights.none.fl_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419767940513792
spelling Value contribution of trifluridine/tipiracil with bevacizumab for the treatment of metastatic colorectal cancer in Catalonia using a multicriteria decision analysisCalle, CandelaElez, ElenaMoreno-Martinez, Maria-EstelaPericay, CarlesGraefenhain, RuthMANZANO, JOSE LUISMetàstasiRecte - Càncer - TractamentCòlon - Càncer - TractamentQuimioteràpia combinadaDISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy ProtocolsDISEASES::Neoplasms::Neoplastic Processes::Neoplasm MetastasisENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectalesOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinadaENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásicaColorectal cancer; Bevacizumab; Decision makingCáncer colorrectal; Bevacizumab; Toma de decisionesCàncer colorectal; Bevacizumab; Presa de decisionsBackground Despite the alternatives available in metastatic colorectal cancer (mCRC), evaluating new therapies continues to be a challenge for clinicians and decision-makers. We aimed to generate a conceptual framework and establish the value criteria for evaluating treatments in mCRC and to apply this framework to assess the value of trifluridine/tipiracil (FTD/TPI) + bevacizumab (BEVA) in advanced lines of therapy for mCRC versus alternatives. Methods A multicriteria decision analysis (MCDA) was conducted according to the modified EVIDEM assessment framework and the following process: defining the decision problem, selecting and structuring the related criteria identified in a literature review, weighting criteria, measurement of performance, and scoring alternatives, to evaluate of mCRC therapies in Catalonia (Spain). An expert panel of five members with experience in cancer treatment in Catalonia was involved. A hierarchical and non-hierarchical weighting of the criteria and sub-criteria was performed. An evidence matrix of available treatments was developed, and experts assigned scores comparing FTD/TPI + BEVA versus alternatives. Results Five value criteria and 18 sub-criteria were selected to evaluate mCRC therapies. According to hierarchical method, efficacy had the highest weight, followed by safety, and lower weights for the rest: cost, guidelines/expert consensus, and epidemiology. In the efficacy dimension, overall survival (OS) had the highest weight, while severe adverse events received the highest score in terms of safety. Non-hierarchical weighting corroborated these results. Treatment with FTD/TPI + BEVA obtained a positive overall value contribution of 0.91, 0.43 points considering only comparative criteria. Comparative criteria were highly important, obtaining values contribution for efficacy, safety and cost of 0.19, 0.15 and 0.12 points, respectively. OS (0.20), progression-free survival (0.19), disease control rate (0.16) and health-related quality of life (0.16) were the most relevant sub-criteria. Conclusion Based on this MCDA, the high value contribution of FTD/TPI + BEVA suggests its substantial benefits over the most used alternatives.The manuscript was prepared with the support of a grant from Servier España.Taylor & FrancisInstitut Català de la Salut[Calle C] Fundació Sant Francesc d’Assís, Barcelona, Spain. [Elez E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Manzano JL] Catalan Institute of Oncology, Hospital Germans Trials i Pujol, Barcelona, Spain. [Moreno-Martinez ME] Servei de Farmàcia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. [Pericay C] Hospital Universitari Mútua de Terrassa, Barcelona, Spain. [Graefenhain R] Servier España, Madrid, SpainVall d'Hebron Barcelona Hospital Campus202620262025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/11351/14293Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésJournal of Pharmaceutical Policy and Practice;18(1)https://doi.org/10.1080/20523211.2025.2567970Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:dnet:scientia____::238c5b2bc00794a4af3600b0d4f5eff62026-06-12T09:38:37Z
score 15,811543

Similares en LA Referencia